[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"ecmo-treatment\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:ecmo-treatment":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,62,78,110],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":33,"overallStatus":49,"whyStopped":4,"lastUpdateSubmitDate":50,"lastUpdatePostDateStruct":51,"startDateStruct":54,"completionDateStruct":56,"leadSponsor":58,"locationsCount":61},"100561711","hemodynamic-monitoring-and-fluid-responsiveness-in-venovenous-extracorporeal-membrane-oxygenation-vv-ecmo---hemodynamecmonitoring-vv-study-100561711",false,"NCT06593717","Hemodynamic Monitoring and Fluid Responsiveness in Venovenous Extracorporeal Membrane Oxygenation (VV ECMO) - \"HemodynamECMOnitoring-VV Study\"","Validation of Techniques for Hemodynamic Monitoring and Prediction of Fluid Responsiveness in Patients Undergoing Venovenous Extracorporeal Membrane Oxygenation - A Prospective Diagnostic Accuracy Study (\"HemodynamECMOnitoring-VV Study\")","Inclusion Criteria:\n\n* Patient receiving VV-ECMO support\n* Age 18 - 75 years\n\nExclusion Criteria:\n\n* Pregnancy\n* Conditions not allowing for passive leg raising maneuvers, e.g. \"open abdomen\", known or suspected elevation of intracranial pressure, recent leg or spinal trauma or orthopedic conditions not permitting leg raising\n* Known ischemic or hemorrhagic stroke within 3 months prior to study enrollment.\n\nSuspicion of raised intracranial pressure is defined as pupil divergence (if not yet further clarified radiographically\u002Fneurologically\u002Fophthalmologically) or signs detected in routine computed tomography scans (compressed or elapsed basal cisterns or midline shift \\> 5 mm.","ALL","18 Years","75 Years",{"count":20,"type":21},30,"ESTIMATED","INTERVENTIONAL",[24],"NA","In extracorporeal membrane oxygenation (ECMO), blood is drawn out of the body via tubes, oxygenated in an artificial lung; and then pumped back into the blood vessels. This allows the supply of oxygen-rich blood to the organs (brain, heart, lungs, kidneys, liver, intestines, etc.) to be maintained.\n\nContinuous monitoring of cardiac function and circulatory status (blood pressure, blood flow to organs) is very important in intensive care medicine in order to control the administration of circulation-supporting medication and infusions. Various devices are routinely used for this task. However, in the specific situation of ECMO treatment, the measurements of these devices could be affected due to the artificial circulation; outside the body.\n\nThe purpose of this study is therefore to test the accuracy of different methods of circulation monitoring during ECMO treatment.",[27,28,29,30,31,32],"ECMO Treatment","ARDS","Pneumonia","Intensive Care","Hemodynamic Monitoring","Fluid Responsiveness",[34,35,28,36,37,31,32,38,39,40,41,42,43,44,45,46,47,48],"VV ECMO","Extracorporeal Membrane Oxygenation","Intensive Care Medicine","Critical Care Medicine","Passive Leg Raising","Pulse Contour Analysis","Transpulmonary Thermodilution","Bioreactance","Pulse Pressure Variation","End-expiratory Occlusion Test","End-inspiratory Occlusion Test","Cardiac Output","LVOT VTI","Stroke Volume","Vena Cava Ultrasound","RECRUITING","2025-09-23",{"date":52,"type":53},"2025-09-29","ACTUAL",{"date":55,"type":53},"2024-05-03",{"date":57,"type":21},"2027-01",{"name":59,"class":60},"Medical University of Vienna","OTHER",1,{"id":63,"slug":64,"hasResults":11,"nctId":65,"briefTitle":66,"officialTitle":67,"acronym":4,"eligibilityCriteria":68,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":69,"targetDuration":4,"studyType":22,"phases":70,"briefSummary":71,"conditions":72,"keywords":73,"overallStatus":49,"whyStopped":4,"lastUpdateSubmitDate":50,"lastUpdatePostDateStruct":74,"startDateStruct":75,"completionDateStruct":76,"leadSponsor":77,"locationsCount":61},"100561714","hemodynamic-monitoring-and-fluid-responsiveness-in-venoarterial-extracorporeal-membrane-oxygenation-va-ecmo---hemodynamecmonitoring-va-study-100561714","NCT06593756","Hemodynamic Monitoring and Fluid Responsiveness in Venoarterial Extracorporeal Membrane Oxygenation (VA ECMO) - \"HemodynamECMOnitoring-VA Study\"","Validation of Techniques for Hemodynamic Monitoring and Prediction of Fluid Responsiveness in Patients Undergoing Venoarterial Extracorporeal Membrane Oxygenation - A Prospective Diagnostic Accuracy Study (\"HemodynamECMOnitoring-VA Study\")","Inclusion Criteria:\n\n* Patient receiving VA ECMO support\n* Age 18 - 75 years\n\nExclusion Criteria:\n\n* Pregnancy\n* Conditions not allowing for passive leg raising maneuvers, e.g. \"open abdomen\", known or suspected elevation of intracranial pressure, recent leg or spinal trauma or orthopedic conditions not permitting leg raising\n* Known ischemic or hemorrhagic stroke within 3 months prior to study enrollment.",{"count":20,"type":21},[24],"In extracorporeal membrane oxygenation (ECMO), blood is drawn out of the body via tubes, oxygenated in an artificial lung; and then pumped back into the blood vessels. This allows the supply of oxygen-rich blood to the organs (brain, heart, lungs, kidneys, liver, intestines, etc.) to be maintained. Continuous monitoring of cardiac function and circulatory status (blood pressure, blood flow to organs) is very important in intensive care medicine in order to control the administration of circulation-supporting medication and infusions. Various devices are routinely used for this task. However, in the specific situation of ECMO treatment, the measurements of these devices could be affected due to the artificial circulation; outside the body. The purpose of this study is therefore to test the accuracy of different methods of circulation monitoring during ECMO treatment.",[27,28,29,30,31,32],[34,35,28,36,37,31,32,38,39,40,41,42,43,44,45,46,47,48],{"date":52,"type":53},{"date":55,"type":53},{"date":57,"type":21},{"name":59,"class":60},{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":84,"eligibilityCriteria":85,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":86,"targetDuration":4,"studyType":22,"phases":88,"briefSummary":89,"conditions":90,"keywords":94,"overallStatus":49,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":109},"100575766","hypothermia-versus-normothermia-after-extracorporeal-cardiopulmonary-resuscitation-for-out-of-hospital-cardiac-arrest-100575766","NCT06776549","Hypothermia Versus Normothermia After Extracorporeal Cardiopulmonary Resuscitation for Out-of-hospital Cardiac Arrest","Hypothermia Versus Normothermia After Extracorporeal Cardiopulmonary Resuscitation for Out-of-hospital Cardiac Arrest: A Cluster Randomized Trial (SAVE-J NEUROTHERM Trial)","J-NEURO","Inclusion Criteria:\n\n* OHCA\n* Age of 18-75 years, known or estimated\n* An initial cardiac arrest rhythm of ventricular fibrillation\u002Fpulseless ventricular tachycardia or pulseless electrical activity\n\nExclusion Criteria:\n\n* ECMO initiated after sustained return of spontaneous circulation (ROSC) and patients with sustained ROSC before ECMO initiation\n* OHCA of presumed non-cardiac etiology\n* Time from emergency call or witnessed arrest to hospital arrival of \\>60 min\n* Time from hospital arrival to ECMO initiation of \\>60 min\n* Pre-hospital ECPR\n* Unavailability of the ECMO heat exchanger for temperature control\n* Glasgow Coma Scale score before temperature control of \\>8\n* Core body temperature upon hospital arrival of ≤32ºC\n* Surgical intervention before temperature control (e.g., surgical intervention for the primary disease or complications related to resuscitation\u002FECMO procedures)\n* Do Not Attempt Resuscitation) order confirmed prior to temperature control\n* Limitations in intensive care before temperature control\n* Known cerebral performance category (CPC) of 3-4 before cardiac arrest\n* Known chronic obstructive pulmonary disease with home oxygen therapy\n* Known or suspected pregnancy\n* Concomitant illness, such as malignancy, shortens life expectancy (180-day survival unlikely)\n* Consent not obtained or withdrawn by the participant or surrogate\n* Other reasons, physician's decision not to enroll the patient",{"count":87,"type":21},468,[24],"The SAVE-J NEUROTHERM trial is a cluster randomized trial that evaluated and compared the mortality risk, neurological outcomes, and adverse events between patients who underwent hypothermia and those who underwent normothermia after extracorporeal cardiopulmonary resuscitation for out-of-hospital cardiac arrest.",[91,27,92,93],"Out-of-hospital Cardiac Arrest (OHCA)","Temperature","Post Cardiac Arrest Syndrome",[95,96,97,98,99],"Cardiac arrest","Out-of-hospital cardiac arrest (OHCA)","Extracorporeal cardiopulmonary resuscitation (ECPR)","Temperature control","Post cardiac arrest syndrome (PCAS)","2025-06-26",{"date":102,"type":53},"2025-06-27",{"date":104,"type":53},"2025-01-06",{"date":106,"type":21},"2028-12-31",{"name":108,"class":60},"Kagawa University",28,{"id":111,"slug":112,"hasResults":11,"nctId":113,"briefTitle":114,"officialTitle":115,"acronym":116,"eligibilityCriteria":117,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":118,"targetDuration":4,"studyType":22,"phases":119,"briefSummary":121,"conditions":122,"keywords":127,"overallStatus":135,"whyStopped":4,"lastUpdateSubmitDate":136,"lastUpdatePostDateStruct":137,"startDateStruct":139,"completionDateStruct":141,"leadSponsor":143,"locationsCount":4},"100587932","phase-4-ciprofols-impact-on-oxygenator-function-in-extracorporeal-membrane-oxygenation-ecmo-patients-100587932","NCT06934811","Ciprofol's Impact on Oxygenator Function in Extracorporeal Membrane Oxygenation (ECMO) Patients","Evaluating the Impact of Ciprofol on Oxygenator Performance in Patients Undergoing Extracorporeal Membrane Oxygenation: A Single-Center Randomized Controlled Trial (CIP-OXY Study)","CIP-OXY","1. Inclusion Criteria:\n\n   * Receiving ECMO therapy with an anticipated duration exceeding 72 hours;\n   * Requiring invasive mechanical ventilation;\n   * Requiring sedation and analgesia treatment.\n2. Exclusion Criteria:\n\n   * BMI \\>45 kg\u002Fm²;\n   * Age \\\u003C18 years;\n   * Severe hepatic (Child-Pugh Class C) or renal failure (eGFR \\\u003C15 mL\u002Fmin\u002F1.73m²);\n   * History of severe psychiatric disorders;\n   * Pregnancy;\n   * Refusal to sign informed consent;\n   * Contraindications to midazolam and propofol use.",{"count":20,"type":21},[120],"PHASE4","This study evaluates the safety and effectiveness of Ciprofol, a new sedative, in critically ill patients receiving Extracorporeal Membrane Oxygenation (ECMO), a life-support system for heart or lung failure. The investigation aims to:\n\nAssess how Ciprofol affects the oxygenator, a critical ECMO component responsible for adding oxygen to blood.\n\nCompare the safety of Ciprofol to midazolam, a commonly used sedative. Eligibility Criteria Adults aged 18 years or older. Patients receiving ECMO and mechanical ventilation for over 72 hours. Individuals requiring sedation for medical procedures. Study Protocol\n\nParticipants will be randomly assigned to one of two groups:\n\nCiprofol Group: Initial sedation dose of 0.1 mg\u002Fkg, adjusted as needed. Midazolam Group: Initial sedation dose of 0.05 mg\u002Fkg, adjusted as needed. Both groups will receive pain management with remifentanil. Sedation levels will be adjusted daily by the clinical team to ensure patient safety and comfort.\n\nOutcome Measures Primary: Oxygenator performance (oxygen and carbon dioxide levels) on Days 3 and 7.\n\nSecondary: Changes in blood triglyceride and clotting marker (D-dimer) levels, oxygenator lifespan before replacement, and safety outcomes such as low blood pressure, respiratory issues, or allergic reactions.\n\nSignificance ECMO patients often require prolonged sedation, but current sedatives like midazolam may contribute to oxygenator damage. Ciprofol's potential for faster recovery and fewer side effects could improve sedation practices and device longevity in this high-risk population.",[27,123,124,125,126],"ARDS (Acute Respiratory Distress Syndrome)","ECMO and Acute MI","Respiratory Failure Patients Treated With ECMO","Shock, Cardiogenic",[128,129,130,131,132,133,134],"Ciprofol","ECMO","Oxygenator function","Sedative","Randomized Controlled Trial","Midazolam","Oxygenator thrombosis","NOT_YET_RECRUITING","2025-04-12",{"date":138,"type":53},"2025-04-18",{"date":140,"type":21},"2025-05-01",{"date":142,"type":21},"2026-12-31",{"name":144,"class":60},"First Affiliated Hospital of Wannan Medical College"]